Growth hormone insensitivity with immune dysfunction caused by a STAT5B mutation in the south of Brazil: evidence for a founder effect

Renata C. Scalco1,2, Fernanda T. Gonçalves3, Hadassa C. Santos4, Mari M. S. G. Cardena3, Carlos A. Tonelli2, Mariana F. A. Funari2, Rosana M. Aracava2, Alexandre C. Pereira4, Cintia Fridman3 and Alexander A. L. Jorge1

1Unidade de Endocrinologia Genética (LIM25), Faculdade de Medicina da Universidade de São Paulo (FMUSP), São Paulo, SP, Brazil.
2Unidade de Endocrinologia do Desenvolvimento, Laboratório de Hormônios e Genética Molecular (LIM42), Faculdade de Medicina da Universidade de São Paulo (FMUSP), São Paulo, SP, Brazil.
3Departamento de Medicina Legal, Ética Médica e Medicina Social e do Trabalho, Laboratório de Imunohematologia e Hematologia Forense (LIM40), Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (HC da FMUSP), São Paulo, SP, Brazil.
4Laboratório de Cardiologia Genética e Molecular, Instituto do Coração (InCor), Faculdade de Medicina da Universidade de São Paulo, São Paulo, SP, Brazil.
5Universidade do Extremo Sul de Santa Catarina, Criciúma, SC, Brazil.

ABSTRACT

Homozygous STAT5B mutations causing growth hormone insensitivity with immune dysfunction were described in 10 patients since 2003, including two Brazilian brothers from the south of Brazil. Our objectives were to evaluate the prevalence of their STAT5B mutation in this region and to analyze the presence of a founder effect. We obtained DNA samples from 1,205 local inhabitants, 48 relatives of the homozygous patients and four individuals of another affected family. Genotyping for STAT5B c.424_427del mutation and for two polymorphic markers around it was done through fragment analysis technique. We also determined Y-chromosome and mtDNA haplotypes and genomic ancestry in heterozygous carriers. We identified seven families with STAT5B c.424_427del mutation, with 33 heterozygous individuals. The minor allelic frequency of this mutation was 0.29% in this population (confidence interval 95% 0.08-0.5%), which is significantly higher than the frequency of other pathogenic STAT5B allele variants observed in public databases (p < 0.001). All heterozygous carriers had the same haplotype present in the homozygous patients, found in only 9.4% of non-carriers (p < 0.001), supporting the existence of a founder effect. The Y-chromosome haplotype, mtDNA and genomic ancestry analysis indicated a European origin of this mutation. Our results provide compelling evidence for a founder effect of STAT5B c.424_427del mutation.

Keywords: founder effect, growth hormone insensitivity, immune dysfunction, STAT5B.

Received: August 24, 2016; Accepted: December 16, 2016.

Introduction

STAT5B (OMIM 604260) is a key protein in the signaling pathway of substances that activate type I class cytokine receptors, such as growth hormone (GH), prolactin and interleukin 2 (IL2). Homozygous mutations in STAT5B gene cause growth hormone insensitivity (Hwa et al., 2011; Scalco et al., 2013), a syndrome characterized by the inability of target tissues to respond to growth hormone. The classic phenotype includes the same clinical signs found in growth hormone deficiency (for example, severe short stature, saddle nose and abdominal obesity), low IGF1 levels and normal to high basal and stimulated GH levels. STAT5B deficient patients also present signs of immune dysregulation, such as recurrent infections, severe eczema and lymphoid interstitial pneumonia, a condition that is often associated to autoimmune diseases and that may evolve to progressive pulmonary fibrosis (Hwa et al., 2011; Scalco et al., 2013). These immune dysfunctions are partly due to a compromised IL2 signaling, since this interleukin is an essential factor in regulatory T-cells development and T-cells activation (Jenks et al., 2013). Furthermore, heterozygous carriers were also shown to be significantly shorter (~ 3.9 cm) than population-matched controls, suggesting a
mild effect of \textit{STAT5B} haploinsufficiency (Scalco et al., 2015).

Since the first case report in 2003, a total of ten patients homozygous for seven different mutations in \textit{STAT5B} were described (Kofoed et al., 2003; Hwa et al., 2005, 2007; Bernasconi et al., 2006; Vidarsdottir et al., 2006; Pugliese-Pires et al., 2010; Scaglia et al., 2012), including two Brazilian brothers homozygous for \textit{STAT5B} c.424_427del mutation (Pugliese-Pires et al., 2010). These brothers were born at Criciúma, a city located in the south of Brazil (at 28°40’39” S 49°22’11” W), with an estimated population of 204,667 individuals according to the Brazilian Institute of Geography and Statistics (IBGE) 2014 census. Their parents, heterozygous for the same mutation, denied consanguinity. Moreover, they reported that an unrelated family in the same city had two kids with similar clinical findings, deceased as a consequence of respiratory failure.

The absence of known consanguinity between the boys’ parents and the presence of other patients with similar conditions in the city led us to hypothesize an increased prevalence of this mutation in the region of Criciúma and a possible founder effect explaining these cases. Furthermore, studying the prevalence of \textit{STAT5B} c.424_427del \textit{STAT5B} mutation could enable the prediction of recurrence of homozygosity for it.

Subjects and Methods

Subjects

The local ethics committee approved this study and all individuals gave their written informed consent. We obtained oral swabs samples from 1,205 adult individuals whose parents or grandparents were born in Criciúma or in the neighboring cities. These subjects were randomly selected among the patients from a health care center in Criciúma. This number of individuals allowed us to evaluate a 0.2% frequency of \textit{STAT5B} c.424_427del allele with 0.99 statistical power. Additionally, we obtained blood samples from 48 relatives of the homozygous boys and in 53 randomly selected non-carriers to evaluate the presence of a founder effect. With the same purpose, we determined Y-chromosome and mtDNA haplotypes and genomic ancestry in one heterozygous carrier from each family affected by \textit{STAT5B} c.424_427del mutation.

\textbf{STAT5B genotyping}

We genotyped all samples for \textit{STAT5B} c.424_427del mutation. Genomic DNA was isolated from oral swabs or from peripheral blood leukocytes using standard techniques. Since \textit{STAT5B} c.424_427del mutation is characterized by the loss of four nucleotides, it was possible to detect it through fragment analysis technique. The region around this mutation was amplified by polymerase chain reaction (PCR) using the following primers: forward 5’ CTCAGTTCCTCCCATCG 3’ and reverse 5’ GGCTCTCCTGGTACTGGA 3’ (amplification conditions are available on request). The products were submitted to capillary electrophoresis in the ABI PRISM 3130 sequencer and then analyzed by the GeneScan® software, both from Applied Biosystems (Foster City, CA, USA).

\textbf{STAT5B c.424_427del allele frequency analysis}

We compared \textit{STAT5B} c.424_427del allele frequency to the frequency of other pathogenic allele variants identified in public population databases: Exome Aggregation Consortium (ExAC - http://exac.broadinstitute.org/) and NHLBI-GO Exome Sequencing Project (ESP - http://evs.gs.washington.edu/EVS/). We considered as pathogenic only the allele variants classified as stop gain or frameshift, since none of the missense variants described in these databases was evaluated by functional studies.

\textbf{Microsatellite analysis}

To evaluate if the presence of this mutation in different families was due to a founder effect, we genotyped two polymorphic markers located less than 1 centimorgan (cM) far from \textit{STAT5B} c.424_427del mutation. These markers, D17S1801 (0.04 cM from the mutation) and D17S932 (0.83 cM from the mutation), were analyzed in the two homozygous patients, 33 heterozygous individuals from seven families harboring the same \textit{STAT5B} mutation and 53 randomly selected non-carriers from the region. They were studied through fragment analysis technique and the PCR products were submitted to capillary electrophoresis in the ABI PRISM 3130 sequencer and then analyzed by the GeneScan® software.

\textbf{Evaluation of ancestry in individuals heterozygous for \textit{STAT5B} c.424_427del mutation}

We assessed genomic, Y-chromosome and mtDNA ancestry in seven individuals (6 males) carrying \textit{STAT5B} c.424_427del mutation, one from each identified family (Figure 1 – subjects I.6, II.2, III.1, IV.2, V.2, VI.2 and VII.1).

\textbf{Genomic ancestry analysis}

Analysis of genomic ancestry was conducted using the Admixture program (Alexander et al., 2009). This software estimates parameter standard errors using bootstrapping. We used an unsupervised approach for ancestry determination, with 200 bootstrap replicates (default) and k = 3 (number of parental populations assumed for the analysis). The analysis was done using 192 Ancestry Informative Markers developed by Santos HC (Santos et al., 2016) and genotyped by OpenArray® Real-Time PCR (Applied
Mitochondrial haplotype analysis

We assumed as reference ancestral populations: Pima and Maya as Amerindians (from the Human Genome Diversity Project - HGDP); YRI (Yoruba in Ibadan, Nigeria), LWK (Luhya in Webuye, Kenya) and ASW (Africans of African Ancestry in SW, USA) as Africans (from the HapMap project); and CEU (Utah Residents (CEPH) with Northern and Western European ancestry) and TSI (Tuscan in Italia) as European (from the HapMap project).

Y-chromosome haplotype analysis

The set of 17 Y-STRs was amplified using the AmpFISTR® YfilerTM kit (Applied Biosystems) which contains the markers DYS19, DYS389 I, DYS389 II, DYS390, DYS391, DYS392, DYS393, DYS385 a/b, DYS438, DYS439, DYS437, DYS448, DYS456, DYS458, DYS635, Y GATA H4. Capillary electrophoresis was done in an ABI PRISM 3130 sequencer, and sizes were assigned to the different fragments using GeneMapper® software. The nomenclature of alleles followed the recommendations of the DNA Commission of the International Society of Forensic Genetics, except for locus Y GATA H4, which was named on the basis of the allelic ladder supplied with the AmpFISTR® YfilerTM kit. The classification of Y-chromosome haplogroup for each male participant genotyped was done using haplogroup prediction program FTDNA 2.0 (http://www.hprg.com/hapest5/index.html).

Mitochondrial haplotype analysis

DNA samples were amplified by a single PCR to analyze the entire sub-regions HV1, HV2 and HV3 of mtDNA control region, using primers L15879 (5'-AATGGG CCTGCTCCTGTAGT-3') and H727 (5'-AGGGTGAACACTGGAACG-3'). These primers were designed using the Primer3 program (http://www-genome.wi.mit.edu/cgi-bin/primer/primer3_www.cgi). PCR products were purified using EXO/SAP (Thermo Scientific Fermentas), and sequencing was done using the BigDye Terminator Cycle Sequencing Kit (Applied Biosystems) according to manufacturer’s protocol. Capillary electrophoresis was performed using the ABI PRISM 3130 sequencer and resultant sequences analyzed using specific software BioEdit (http://www.mbio.ncsu.edu/BioEdit/BioEdit.html). The sequences obtained were compared with the Cambridge Reference Sequence (rCRS) (Andrews et al., 1999) for final definition of haplotypes using the program Haplosite (http://www.haplosite.com/haplosearch/). Classification of mtDNA haplogroups was done using HaploGrep program (http://haplogrep.uibk.ac.at/).

Statistical analysis

We evaluated the differences between the allele frequency of STAT5B c.424_427del mutation and the frequencies of each pathogenic allele identified in ExAC and ESP databases by using chi-square test. A p value less than 0.05 was considered statistically significant. All statistical calculations were carried out using SigmaStat version 3.5 (Systat Software Inc. Chicago, IL).

Results

STAT5B genotyping

Among the 1,205 evaluated individuals from the local population, seven were identified as heterozygous for STAT5B c.424_427del mutation. Two of them were later found to be 3rd and 4th degree relatives of the previously described homozygous patients (Figure 1). The other five were from four apparently unrelated families. Moreover, in the family who lost two children with a similar phenotype to the homozygous boys, the parents were first cousins and heterozygous for STAT5B c.424_427del mutation. Consequently, it is possible to infer that their deceased son and daughter were homozygous for this mutation and died of progressive pulmonary fibrosis.

In total, we identified seven apparently independent families with STAT5B c.424_427del mutation in Criciúma (Figure 1), with 33 heterozygous individuals. Therefore, the minor allele frequency of this mutation at Criciúma was 0.29% (Confidence interval (CI) 95% of 0.08 to 0.5%). This allele frequency was significantly higher than the frequency of other pathogenic STAT5B allele variants observed in public databases (p < 0.001, Table 1 and Supplementary Table S1). Six of these families had ancestors born in Tubarão, a city located 60 km from Criciúma. In one family it was not possible to trace its geographic origin.

Microsatellite analysis

Eleven different alleles were identified for D17S932 marker, ranging from 178 to 202 base pairs (bp), and nine alleles were identified for D17S1801 marker, ranging from 220 to 244 bp. The allelic frequencies were 24% and 53%, respectively.

The analysis of these markers around STAT5B showed that the two homozygous patients had the haplotype D17S932 196, D17S1801 242. Both markers were identified in all heterozygous individuals (100%) and their phase has been inferred from families with unambiguous haplotypes. However, this combination of markers was found in only 5 of 53 evaluated non-carriers (9.4%), which was significantly different from heterozygous carriers (considering one individual per family, p < 0.001). Based on this result, it is unlikely that STAT5B c.424_427del mutation associated with 196-242 haplotype was derived from independent origins. The alternative hypothesis is that individuals harboring the mutation share a common ancestor, from whom they inherited this haplotype.

Microsatellite analysis

Eleven different alleles were identified for D17S932 marker, ranging from 178 to 202 base pairs (bp), and nine alleles were identified for D17S1801 marker, ranging from 220 to 244 bp. The allelic frequencies were 24% and 53%, respectively.

The analysis of these markers around STAT5B showed that the two homozygous patients had the haplotype D17S932 196, D17S1801 242. Both markers were identified in all heterozygous individuals (100%) and their phase has been inferred from families with unambiguous haplotypes. However, this combination of markers was found in only 5 of 53 evaluated non-carriers (9.4%), which was significantly different from heterozygous carriers (considering one individual per family, p < 0.001). Based on this result, it is unlikely that STAT5B c.424_427del mutation associated with 196-242 haplotype was derived from independent origins. The alternative hypothesis is that individuals harboring the mutation share a common ancestor, from whom they inherited this haplotype.
Ancestry analysis

The ancestry in all heterozygous subjects evaluated (one from each affected family) was predominately assigned to a cluster defined by its maximum frequency in European populations (median 85%, p25-p75 80.9-89.3%). African and Amerindian ancestries represented 7.4% (p25-p75 3.1-9.1%) and 7.2% (p25-p75 6.5-14%) of the genomes analyzed (Table 2).

Regarding the paternal lineage origin, the haplogroup R1b, which is predominantly found in Western Europe, was present in three of them. Two of them had the haplogroup J (J1 e J2a1), found mainly in the Middle East, and one individual had the rare haplogroup I2a1 (Table 2). About the maternal lineage origin, the haplotypes B4 and C1, found in indigenous peoples of the Americas, were present in three subjects. The haplotype H, the most common maternal lineage in Europe, was found in two other individuals. One subject had the haplotype K1a, present in all Europe but more prevalent in Northwest Europe, and the last one had the haplotype HV, present in the Middle East, Italy and Eastern Europe.

Discussion

Growth hormone insensitivity with immune dysfunction (OMIM 245590) caused by STAT5B mutations is a rare but life threatening disease in which severe short stature is accompanied by the burden of recurrent infections, autoimmune diseases and progressive pulmonary fibrosis. Four out of 10 described patients died of respiratory failure, including one of them who was submitted to lung transplantation when he was 17.5 years old. There is no treatment available at present, but some researchers consider that early bone marrow transplantation could prevent the pulmonary disease. Inheritance is autosomal recessive and none of the described patients had compound heterozygous mutations. Family history was available in eight cases and consanguinity was not identified in half of them (Bernas-
The presence of the same haplotype in all evaluated STAT5B c.424_427del mutation carriers and the relative rarity of the same haplotype in non-carrier individuals from the same region indicate a common origin of this mutation and the existence of a founder effect justifying its relatively high prevalence in Criciúma. Studies analyzing other defects in GH/IGF1 axis presented similar findings, in which a founder effect explained the presence of the same mutation in families apparently not related (Kamijo et al., 2004).

Criciúma was founded in 1880 with the arrival of 22 families of Italian immigrants from the Veneto region, which was followed by the arrival of Portuguese, German and Polish immigrants. It was originally a part of Tubarão, the city where most families with STAT5B c.424_427del mutation had their origin. Tubarão was first occupied in 1774 by Portuguese and Azoreans immigrants and Brazilians of mixed ancestry; it then received Italian, German and Polish immigrants. It was originally a part of Tubarão, which was followed by the arrival of Portuguese, German families of Italian immigrants from the Veneto region, showing the existence of marriages among European descendents, but also between them and Native Americans, as observed in other Latin American populations (Alves-Silva et al., 2000).

In conclusion, our findings provide evidence to the existence of a founder effect explaining a relatively elevated prevalence of STAT5B c.424_427del mutation in the south of Brazil. According to Y-chromosome haplotype analysis, we hypothesize that Portuguese immigrants or descendents carried this mutation to Tubarão and from there to Criciúma. Health professionals from Criciúma and its neighboring cities, including Tubarão, should be aware of the increased risk of homozygosity for this mutation in the region so that new cases are early diagnosed.

Acknowledgments

This work was financially supported by Grants 2013/03236-5, 2010/19809-6 (to A.A.L.J.), 2011/15078-0 and 2016/03318-0 (to R.C.S) from the São Paulo State Research Foundation (FAPESP); and Grant 301871/2016-7 (to A.A.L.J.) from the National Council for Scientific and Technological Development (CNPq). The authors thank Dr. Julio Cezar Cechinel from Laboratorio Pasteur – Criciúma, SC, Brazil for performing laboratory tests in individuals from families with STAT5B c.424_427del mutation.

References

Alexander DH, Novembre J and Lange K (2009) Fast model-based estimation of ancestry in unrelated individuals. Genome Res 19:1655-1664.
Alves-Silva J, da Silva Santos M, Guimaraes PE, Ferreira AC, Bandelt HJ, Pena SD and Prado VF (2000) The ancestry of Brazilian mtDNA lineages. Am J Hum Genet 67:444-461.
Andrews RM, Kubacka I, Chinnery PF, Lightowlers RN, Turnbull DM and Howell N (1999) Reanalysis and revision of the Cambridge reference sequence for human mitochondrial DNA. Nat Genet 23:147.
Bernasconi A, Marino R, Ribas A, Rossi J, Ciaccio M, Oleastro M, Ormani A, Paz R, Rivalora MA, Zelazko M, et al. (2006) Characterization of immunodeficiency in a patient with growth hormone insensitivity secondary to a novel STAT5b gene mutation. Pediatrics 118:e1584-1592.
Hwa V, Little B, Adiyaman P, Kofoed EM, Pratt KL, Ocal G, Berberoglu M and Rosenfeld RG (2005) Severe growth hormone insensitivity resulting from total absence of signal transducer and activator of transcription 5b. J Clin Endocrinol Metab 90:4260-4266.

Hwa V, Camacho-Hubner C, Little BM, David A, Metherell LA, El-Khatib N, Savage MO and Rosenfeld RG (2007) Growth hormone insensitivity and severe short stature in siblings: a novel mutation at the exon 13-intron 13 junction of the STAT5b gene. Horm Res 68:218-224.

Hwa V, Nadeau K, Wit JM and Rosenfeld RG (2011) STAT5b deficiency: lessons from STAT5b gene mutations. Best Pract Res Clin Endocrinol Metab 25:61-75.

Jenks JA, Seki S, Kanai T, Huang J, Morgan AA, Scalco RC, Nath R, Bucayu R, Wit JM, Al-Herz W, et al. (2013) Differentiating the roles of STAT5B and STAT5A in human CD4+ T cells. Clin Immunol 148:227-236.

Kamijo T, Hayashi Y, Seo H, Yamamoto M, Ogawa M, Choski CS, Sawant NJ, Colaco MP and Desai MP (2004) A nonsense mutation (E72X) in growth hormone releasing hormone receptor (GHRHR) gene is the major cause of familial isolated growth hormone deficiency in Western region of India: founder effect suggested by analysis of dinucleotide repeat polymorphism close to GHRHR gene. Growth Horm IGF Res 14:394-401.

Kofoed EM, Hwa V, Little B, Woods KA, Buckway CK, Tsubaki J, Pratt KL, Bezrodnik L, Jasper H, Tepper A, et al. (2003) Growth hormone insensitivity associated with a STAT5b mutation. N Engl J Med 349:1139-1147.

Pugliese-Pires PN, Tonelli CA, Dora JM, Silva PC, Czepielewski M, Simoni G, Arnhold IJ and Jorge AA (2010) A novel STAT5b mutation causing GH insensitivity syndrome associated with hyperprolactinemia and immune dysfunction in two male siblings. Eur J Endocrinol 163:349-355.

Santos HC, Horimoto AV, Tarazona-Santos E, Rodrigues-Soares F, Barreto ML, Horta BL, Lima-Costa MF, Gouveia MH, Machado M, Silva TM, et al. (2016) A minimum set of ancestry informative markers for determining admixture proportions in a mixed American population: the Brazilian set. Eur Hum Genet 24:725-731.

Scaglia PA, Martinez AS, Feigerlova E, Bezrodnik L, Gaillard MI, Di Giovanni D, Ballerini MG, Jasper HG, Heinrich JJ, Fang P, et al. (2012) A novel missense mutation in the SH2 domain of the STAT5B gene results in a transcriptionally inactive STAT5b associated with severe IGF-I deficiency, immune dysfunction, and lack of pulmonary disease. J Clin Endocrinol Metab 97:E830-839.

Scalco RC, Pugliese-Pires PN amnd Jorge AA (2013) STAT5B deficiency: a new growth hormone insensitivity syndrome associated to immunological dysfunction. Arq Bras Endocrinol Metabol 57:333-338.

Scalco RC, Hwa V, Domene HM, Jasper HG, Belgorosky A, Marino R, Pereira AM, Tonelli CA, Wit JM, Rosenfeld RG, et al. (2015) STAT5B mutations in heterozygous state have negative impact on height: Another clue in human stature heritability. Eur J Endocrinol 173:291-296.

Vidarsdottir S, Walenkamp MJ, Pereira AM, Karperien M, van Doorn J, van Duyvenvoorde HA, White S, Breuning MH, Roelfsema F, Kruithof MF, et al. (2006) Clinical and biochemical characteristics of a male patient with a novel homozygous STAT5b mutation. J Clin Endocrinol Metab 91:3482-3485.

Scalco et al.

Supplementary Material

Supplementary material is available for this article:
Table S1 - Allele frequency comparison of the present study with ExAC data.

License information: This is an open-access article distributed under the terms of the Creative Commons Attribution License (type CC-BY), which permits unrestricted use, distribution and reproduction in any medium, provided the original article is properly cited.